Temozolomide versus 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial

被引：0
|
作者：
机构：
来源：
International Journal of Radiation Oncology Biology Physics | 2013年 / 85卷 / 02期
关键词：
Compendex;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：284 / 285
相关论文
共 50 条
  • [41] Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Wilkins, Anna
    Mossop, Helen
    Syndikus, Isabel
    Khoo, Vincent
    Bloomfield, David
    Parker, Chris
    Logue, John
    Scrase, Christopher
    Patterson, Helen
    Birtle, Alison
    Staffurth, John
    Malik, Zafar
    Panades, Miguel
    Eswar, Chinnamani
    Graham, John
    Russell, Martin
    Kirkbride, Peter
    O'Sullivan, Joe M.
    Gao, Annie
    Cruickshank, Clare
    Griffin, Clare
    Dearnaley, David
    Hall, Emma
    LANCET ONCOLOGY, 2015, 16 (16): : 1605 - 1616
  • [42] 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non- inferiority trial
    Hoskin, Peter J.
    Kirkwood, Amy A.
    Popova, Bilyana
    Smith, Paul
    Robinson, Martin
    Gallop-Evans, Eve
    Coltart, Stewart
    Illidge, Timothy
    Madhavan, Krishnaswamy
    Brammer, Caroline
    Diez, Patricia
    Jack, Andrew
    Syndikus, Isabel
    LANCET ONCOLOGY, 2014, 15 (04): : 457 - 463
  • [43] Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial
    Stephanie E Combs
    Iris Burkholder
    Lutz Edler
    Stefan Rieken
    Daniel Habermehl
    Oliver Jäkel
    Thomas Haberer
    Renate Haselmann
    Andreas Unterberg
    Wolfgang Wick
    Jürgen Debus
    BMC Cancer, 10
  • [44] Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial
    Combs, Stephanie E.
    Burkholder, Iris
    Edler, Lutz
    Rieken, Stefan
    Habermehl, Daniel
    Jaekel, Oliver
    Haberer, Thomas
    Haselmann, Renate
    Unterberg, Andreas
    Wick, Wolfgang
    Debus, Juergen
    BMC CANCER, 2010, 10
  • [45] Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
    Vaidya, Jayant S.
    Joseph, David J.
    Tobias, Jeffrey S.
    Bulsara, Max
    Wenz, Frederik
    Saunders, Christobel
    Alvarado, Michael
    Flyger, Henrik L.
    Massarut, Samuele
    Eiermann, Wolfgang
    Keshtgar, Mohammed
    Dewar, John
    Kraus-Tiefenbacher, Uta
    Suetterlin, Marc
    Esserman, Laura
    Holtveg, Helle M. R.
    Roncadin, Mario
    Pigorsch, Steffi
    Metaxas, Marinos
    Falzon, Mary
    Matthews, April
    Corica, Tammy
    Williams, Norman R.
    Baum, Michael
    LANCET, 2010, 376 (9735): : 91 - 102
  • [46] Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
    Sahgal, Arjun
    Myrehaug, Sten D.
    Siva, Shankar
    Masucci, Giuseppina L.
    Maralani, Pejman J.
    Brundage, Michael
    Butler, James
    Chow, Edward
    Fehlings, Michael G.
    Foote, Mathew
    Gabos, Zsolt
    Greenspoon, Jeffrey
    Kerba, Marc
    Lee, Young
    Liu, Mitchell
    Liu, Stanley K.
    Thibault, Isabelle
    Wong, Rebecca K.
    Hum, Maaike
    Ding, Keyue
    Parulekar, Wendy R.
    LANCET ONCOLOGY, 2021, 22 (07): : 1023 - 1033
  • [47] Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial
    Mao, Yan-Ping
    Wang, Shun-Xin
    Gao, Tian-Sheng
    Zhang, Ning
    Liang, Xiao-Yu
    Xie, Fang-Yun
    Zhang, Yuan
    Zhou, Guan-Qun
    Guo, Rui
    Luo, Wei-Jie
    Li, Yong-Jie
    Liang, Shao-Qiang
    Lin, Li
    Li, Wen-Fei
    Liu, Xu
    Xu, Cheng
    Chen, Yu -Pei
    Lv, Jia-Wei
    Huang, Shao-Hui
    Liu, Li-Zhi
    Li, Ji-Bin
    Chen, Lei
    Sun, Ying
    Ma, Jun
    Tang, Ling-Long
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [48] Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.
    Herrlinger, Ulrich
    Schaefer, Niklas
    Steinbach, Joachim Peter
    Weyerbrock, Astrid
    Hau, Peter
    Goldbrunner, Roland
    Friedrich, Franziska
    Stockhammer, Florian
    Ringel, Florian
    Braun, Christian
    Kohnen, Ralf
    Leutgeb, Barbara
    Belka, Claus
    Urbach, Horst
    Stummer, Walter
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 196 (05): : 1445 - 1445
  • [50] Hypofractionated Radiotherapy (XRT) Plus Concurrent and Adjuvant Versus Salvage Temozolomide (TMZ) in Elderly Patients with Glioblastoma Multiform: A Review of Ten-year Single Institutional Experience
    Cao, J. Q.
    Bauman, G. S.
    Fisher, B. J.
    Macdonald, D. R.
    Megyesi, J. F.
    Watling, C. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S167 - S167
12345